TL;DR: Cigna Healthcare modified policy A008 (ad_a008_authorized_generics) covering authorized generic drugs, effective February 28, 2026. Here's what your pharmacy billing and formulary verification workflows need to account for.
Cigna Healthcare updated its Authorized Generics administrative policy (A008) on February 28, 2026. The policy governs how Cigna covers authorized generic drugs versus their reference brand drugs across benefit plans and formularies. This policy does not list specific CPT or HCPCS codes — coverage determinations are formulary-driven and plan-specific. The real risk for your team is processing claims without confirming which version of a drug — brand or authorized generic — a given member's plan actually covers.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Authorized Generics |
| Policy Code | ad_a008_authorized_generics |
| Change Type | Modified |
| Effective Date | February 28, 2026 |
| Impact Level | Medium |
| Specialties Affected | Pharmacy, specialty pharmacy, any practice dispensing or billing drugs under medical or pharmacy benefit |
| Key Action | Verify each member's benefit plan and formulary before submitting claims for authorized generic or reference brand drugs — do not assume coverage based on drug class alone |
Cigna Authorized Generic Drug Coverage Policy and Medical Necessity Requirements 2026
The Cigna authorized generic drug coverage policy draws a sharp line between two things billing teams often treat as interchangeable: the reference brand drug and its authorized generic.
An authorized generic drug is not a traditional generic. It's a drug sold under a different labeler code, product code, trade name, trademark, or packaging — but it's made under the same FDA-approved new drug application (NDA) as the brand. Specifically, Cigna defines it as any drug marketed under an NDA approved under section 505(c) of the Federal Food, Drug and Cosmetic Act (FFDCA). That's a meaningful legal and formulary distinction.
Here's the core problem for billing: Cigna covers either the reference brand drug, the authorized generic, or both — depending on the individual member's benefit plan and formulary. There is no universal answer. A drug covered as a brand for one member may be covered only as an authorized generic for another. Your billing team cannot apply one rule across all Cigna members.
Medical necessity, in the traditional clinical sense, is not the primary driver here. Coverage is formulary-driven. But the policy does include one medical necessity-adjacent rule: a non-covered formulary alternative can only be covered when the covered formulary alternative is not available in the market. That's a narrow carve-out, and it requires documentation. If you're billing for a non-formulary option, you need evidence the formulary alternative was genuinely unavailable — not just that the prescriber preferred a different product.
Prior authorization requirements are not spelled out in A008 itself. But given that coverage varies by plan and formulary, prior authorization may apply at the plan level for specific drugs. Check the member's benefit plan document before assuming a drug is covered without prior auth. Reimbursement for authorized generics versus brand drugs can also differ significantly depending on how the formulary tiers are structured.
Cigna Authorized Generic Drug Exclusions and Non-Covered Indications
The policy has one clear exclusion pattern: if a covered formulary alternative exists and is available in the market, Cigna will not cover the non-covered alternative.
This sounds simple. In practice, it creates claim denial risk for teams that don't verify formulary status before billing. If your pharmacy bills an authorized generic when the plan's formulary only covers the reference brand — or vice versa — you're looking at a denial that won't be obvious from the EOB without cross-referencing the formulary.
The policy also explicitly states that not every authorized generic is addressed in A008. The omission of a specific authorized generic from the policy tables does not mean that drug is covered or excluded. It means you have to go to the member's benefit plan document and formulary to find out. That's not a shortcut — it's the only path to a clean claim.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Reference brand drug listed in member's formulary | Covered | Plan/formulary-specific — no universal CPT/HCPCS assigned in this policy | Coverage confirmed only by member benefit plan and formulary |
| Authorized generic drug listed in member's formulary | Covered | Plan/formulary-specific — no universal CPT/HCPCS assigned in this policy | Coverage varies by plan; Cigna may cover one, both, or neither |
| Both reference brand and authorized generic | Covered (plan-dependent) | Plan/formulary-specific | Some plans cover both; verify before billing |
| Non-covered formulary alternative when covered alternative is unavailable in market | Covered (limited exception) | Plan/formulary-specific | Requires documentation that the covered alternative is genuinely unavailable |
| Non-covered formulary alternative when covered alternative is available | Not Covered | N/A | No exceptions; claim will deny |
| Authorized generics not addressed in policy tables | Coverage status unknown | N/A | Must be verified against member's benefit plan document and formulary |
Cigna Authorized Generic Drug Billing Guidelines and Action Items 2026
The effective date of February 28, 2026 is already here. If your team hasn't updated its verification workflow for Cigna authorized generics billing, do it now.
| # | Action Item |
|---|---|
| 1 | Pull the member's benefit plan document and formulary before billing. This is not optional for Cigna authorized generic claims. The policy is explicit: coverage varies by plan and formulary. Don't assume a drug class or therapeutic category tells you what's covered for a specific member. |
| 2 | Identify whether the claim involves a reference brand drug, an authorized generic, or both. These are billed differently and covered differently across Cigna plans. Train your billing team to recognize authorized generics — they share an NDA with the brand but carry a different labeler code or trade name. That distinction drives coverage. |
| 3 | Document market unavailability when billing a non-covered alternative. If a member's formulary alternative is unavailable in the market and you're billing for a non-formulary option, document it. The policy allows coverage in this narrow case, but only with evidence. A prescriber note saying "preferred" is not sufficient. You need documentation showing the covered formulary drug is not available. |
| 4 | Check prior authorization requirements at the plan level. Policy A008 doesn't specify prior auth requirements — but individual benefit plans may require prior authorization for specific authorized generics or reference brand drugs. Run eligibility and benefit verification before dispensing or billing to catch any prior auth requirements that apply to the specific drug and member. |
| 5 | Audit recent Cigna claims for authorized generic drugs filed before February 28, 2026. If your team was applying a single coverage rule across all Cigna members for authorized generics, audit those claims. Denials or underpayments may be traceable to mismatched formulary status. Identify any patterns and correct your processes before they compound. |
| 6 | Don't treat policy table omissions as coverage confirmation. Cigna says it directly: if an authorized generic isn't addressed in A008, that tells you nothing about whether it's covered. Your billing team needs to understand this. An omission is not a green light. |
| 7 | Loop in your compliance officer if you're unsure how this applies to your drug mix. Formulary-driven coverage policies create compliance exposure when teams apply shortcuts. If your practice or pharmacy dispenses a significant volume of drugs that fall into the authorized generic category, ask your compliance officer to review your verification process against the February 28, 2026 policy update before your next billing cycle. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Authorized Generics Under ad_a008_authorized_generics
Cigna's A008 policy does not list specific CPT codes, HCPCS codes, or ICD-10-CM diagnosis codes. Coverage is determined entirely at the benefit plan and formulary level, not by procedure code.
This is a meaningful difference from most clinical coverage policies. There is no universal code-to-coverage mapping to apply. Authorized generic drug billing follows the drug-specific NDC (National Drug Code) and the member's formulary tier — not a CPT or HCPCS code that a billing team can standardize across claims.
What this means practically: your claim denial prevention for authorized generics depends on formulary verification, not charge capture. The coding is downstream of the formulary check. If the formulary check fails, the code won't save you.
If your billing system uses drug-specific coding — NDC codes on pharmacy claims or J-codes on medical benefit claims for specialty drugs — those codes will be the relevant identifiers. But A008 does not specify them. Cross-reference the applicable drug's NDC against the member's formulary, then bill accordingly.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.